藥品名稱
drug name | Measles & Mumps & Rubella Vaccine 0.5 ml/1 dose/vial (Priorix) 派立克麻疹、腮腺炎、德國麻疹疫苗【自費】 |
| 藥檔狀態 | 使用中 |
成 份
Ingredient | RUBELLA VACCINE LIVE ATTENUATED, MEASLES VACCINE, LIVE ATTENUATED, MUMPS VACCINE LIVE ATTENUATED |
| 單位含量 | 0.5 mL/1 dose/vial |
| Dosage Forms | 1 dose/vial |
| 顏 色 | |
| Color | |
| 形 狀 | |
| Shape | |
| 劑 型 | 針劑/注射 |
| Dose Form | |
大 小
Size | |
標 示
outward | |
廠商名稱
Manufacturer | 荷商葛蘭素史克藥廠股份有限公司臺灣分公司 |
製 造 商
Manufacturer | FIDIA FARMACEUTICI S.P.A. |
字 號
Product ID | 衛署菌疫輸字第000510號 |
藥理分類
Pharmacologic Category | Biologic and immunologic agents/Vaccines-virus (live)/ |
作用機轉
Mechanism of action | As a live, attenuated vaccine, MMR vaccine offers active immunity to disease caused by the measles, mumps, and rubella viruses |
| 用途/適應症 | 麻疹、腮腺炎、德國麻疹疫苗 |
| Use |
麻疹、腮腺炎及德國麻疹之主動免疫。
|
衛福部核准適用症狀
MOHW approved indications |
麻疹、腮腺炎及德國麻疹之主動免疫。
|
| 常用劑量 | 立刻使用1vial
(藥品劑量會因人或病情增減，請依照醫師指示服用。) |
| Dose |
SC：Infants <12 months: if there is risk of exposure to measles, single-antigen measles vaccine should be administered at 6-11 months of age with a second dose (of MMR) at >12 months of age. Children >12 months: 0.5ml at 12 months and then repeated at 4-6 years of age. If the second dose was not received, the schedule should be completed by the 11- to 12-years old visit. Administer in outer aspect of the upper arm. Recommended age of primary immuniztion is 12-15 months; revaccination is recommended prior to elementary school
|
懷孕分級
Pregnancy Risk Factor |
C
-
[FDA(美國食品及藥物管理局)懷孕分級說明:
A：對照試驗無法證實懷孕初期及後期使用會危害胎兒。
B：動物試驗無法證實對胎兒有害，但缺乏人類對照試驗；或動物試驗有副作用報告，但無法證實對懷孕初期及後期之胎兒有害。
C：動物實驗中對胎兒有害但缺乏孕婦對照實驗；或無動物及孕婦試驗。
D：證實對胎兒有害，但疾病對孕婦有生命威脅或較安全藥品無法使用或無效時可使用。
X：證實對胎兒有害，且使用後危害大於可能的益處。孕婦及可能懷孕婦女禁用。]
|
| 禁忌症 |
1. 不可用於對Neomycin或本疫苗的其他成分產生全身性過敏症狀患者；對 Neomycin有接觸性皮膚炎病史者，非本產品禁忌症。
2. 禁用於過去施打麻疹、腮腺炎和(或)德國麻疹後曾出現嚴重過敏徵狀者。
3. 禁用於有嚴重體液或細胞(原發或後天 )免疫不全患者，如人類免疫缺損病毒感染徵候群。
4. 禁用於懷孕婦女。接種疫苗後一個月內應避免懷孕。
|
| Contraindications |
Hypersensitivity to measles, mumps, and/or rubella vaccine or any component of the formulation (including neomycin); current febrile respiratory illness or other febrile infection; patients receiving immunosuppressive therapy (does not include corticosteroids as replacement therapy); primary and acquired immunodeficiency states; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; family history of congenital or hereditary immunodeficiency (until immune competence in the vaccine recipient is demonstrated); pregnancy
|
| 常見副作用 | 關節痛、肌肉疼痛、發熱、注射部位不適。 |
| Common adverse drug reactions | Joint pain, Muscle pain, Fever, Discomfort in the injection site. |
| Adverse Reactions |
Arthritis, arthralgia, myalgia, cold symptoms, fever, injection site pain/erythema, lymphadenopathy, rash, anaphylaxis, encephalitis, polyneuritis, polyneuropathy, optic neuritis, Guillain-Barre syndrome, Stevens-Johnson syndrome, thrombocytopenia
|
監測
Monitoring |
Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.
|
| 警語與注意事項 | 冷藏;不可口服 |
| Warnings & precautions | Not for oral adminstration. Should be refrigerated between 2-8 ℃. |
| 針劑溶解條件 |
|
| 針劑稀釋條件 |
|
| 針劑不相容性 |
不可與其他的疫苗在同一支注射針筒中混合。
|
| 針劑施打條件 |
須皮下注射。
不可直接注射於血管內。
|
| 針劑保存安定性 |
2-8℃，冷藏及避光儲存 。
稀釋液可與疫苗一起貯存於冰箱中或將其單獨置於室溫中，切勿冷凍。
稀釋後請儘快使用。若需貯存，則將此稀釋後的疫苗置於其原來小瓶中貯存於2-8℃黑暗處。若於8小時內未使用完即需丟棄。
|
最近修改日期時間
Updated | 6/22/2021 9:00:55 AM |